Abiopharma

Cabbacis Inc (OTCQB: CABI) wholly owns Cabbacis LLC, a development stage, U.S. federally-licensed, tobacco product manufacturer founded in 2021 and focused on harm reduction products that contain about 95 percent less nicotine than that of leading U.S. cigarette brands. The mission of Cabbacis is to reduce the harm caused by smoking with its proprietary reduced-nicotine iBlend® products in development. The Company’s worldwide patent portfolio includes 34 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries. Cabbacis holds 6 U.S. patents. Reduced-nicotine cigarettes without hemp have been evaluated in dozens of independent studies and contain about 95 percent less nicotine than conventional cigarettes. Results demonstrate, as reviewed in Donny and White 2022, that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days. The Company believes including hemp flower into reduced-nicotine cigarettes improves sensory characteristics and may potentially improve effectiveness due to the presence of non-THC cannabinoids. ‍ According to Grand View Research, the global tobacco market was estimated at $886 billion in 2023 and is expected to grow at a CAGR of 2.5% from 2024 to 2030.

Additional info from OTC:
Cabbacis Inc (OTCQB: CABI) wholly owns Cabbacis LLC, a development stage, U.S. federally-licensed, tobacco product manufacturer founded in 2021 and focused on harm reduction products that contain about 95 percent less nicotine than that of leading U.S. cigarette brands. The mission of Cabbacis is to reduce the harm caused by smoking with its proprietary reduced-nicotine iBlend® products in development. The Company’s worldwide patent portfolio includes 34 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries. Cabbacis holds 6 U.S. patents. Reduced-nicotine cigarettes without hemp have been evaluated in dozens of independent studies and contain about 95 percent less nicotine than conventional cigarettes. Results demonstrate, as reviewed in Donny and White 2022, that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days. The Company believes including hemp flower into reduced-nicotine cigarettes improves sensory characteristics and may potentially improve effectiveness due to the presence of non-THC cannabinoids. ‍ According to Grand View Research, the global tobacco market was estimated at $886 billion in 2023 and is expected to grow at a CAGR of 2.5% from 2024 to 2030.